Dyne Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $3,788 |
Gross Profit | -400 | -386 | 3,221 | |
EBITDA | -105,221 | -71,962 | -68,771 | -67,289 |
EBIT | -105,659 | -72,361 | -69,157 | -67,856 |
Net Income | -97,125 | -65,102 | -65,649 | -66,638 |
Net Change In Cash | 0 | 0 | 0 | 3,788 |
Free Cash Flow | -74,882 | -55,725 | -78,728 | -35,088 |
Cash | 532,163 | 608,196 | 272,035 | 121,626 |
Basic Shares | 100,882 | 92,507 | 81,043 | 61,393 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -2,461 | -3,345 | -1,088 | -700 |
EBITDA | -233,476 | -169,279 | -148,203 | -57,947 |
EBIT | -235,149 | -170,962 | -149,291 | -58,647 |
Net Income | -235,937 | -165,237 | -149,283 | -58,737 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -188,887 | -156,712 | -123,181 | -47,669 |
Cash | 121,626 | 172,147 | 200,825 | 300,852 |
Basic Shares | 59,683 | 51,976 | 50,895 | 14,395 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.96 |
2024-06-30 | -$0.70 |
2024-03-31 | -$0.81 |
2023-12-31 | -$1.09 |
